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ABSTRACT 
BACKGROUND: Chronic anticoagulation is recommended in patients with hypertrophic 
cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral 
anticoagulants (NOACs) are an alternative to warfarin, but there are limited data to support 
their use in patients with HCM and AF. We sought to compare thromboembolic events, 
bleeding, and mortality between NOAC and warfarin in patients with HCM and AF. 
METHODS: From the Korean National Health Insurance Service (NHIS) database during 
the period from January 1, 2011 to December 31, 2016, we identified a warfarin-treated 
group of patients with HCM and AF (n = 955) who were compared with a 1:2 propensity-
matched NOAC treated group (n = 1,504). 
RESULTS: After a median follow-up of 15 months, the incidence rates of ischemic stroke 
and major bleeding were similar between NOAC- and warfarin-treated patients with HCM 
and AF. NOAC-treated patients had lower incidence rates for all-cause mortality (5.11 and 
10.13 events per 100 person-years for NOAC and warfarin groups) and the composite of fatal 
cardiovascular events (0.77 and 1.80 events per 100 person-years). Compared with warfarin, 
use of NOACs was associated with a significantly lower risk of all cause-mortality (hazard 
ratio [HR]: 0.43, 95% confidence interval [CI]: 0.32-0.57) and composite fatal cardiovascular 
events (HR: 0.39, 95% CI: 0.18-0.82).  
CONCLUSIONS: Compared with warfarin, patients with HCM and AF on NOACs had 
similar stroke and major bleeding risks, but lower all-cause mortality and composite fatal 
cardiovascular events. Our data suggest that patients with HCM and AF can be safely and 
effectively treated with NOACs. 
Keywords: Atrial fibrillation, hypertrophic cardiomyopathy, stroke, non-vitamin K antagonist 
oral anticoagulants.  
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Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the 
general population,1 and stroke prevention is the principal management priority in patients 
with AF, given its association with a five-fold increase in stroke risk.1-3 Patients with 
hypertrophic cardiomyopathy (HCM) have a four- to six-fold greater likelihood of 
developing AF compared with the general population.4-7 AF is the most common arrhythmia 
in HCM and has been known to be associated with a high risk of stroke and systemic embolic 
events as well as heart failure-related mortality.4,5,7 
Currently, the CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 
(doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular 
disease, age 65 to 74, female] score8 is widely used in most guidelines for stroke prevention 
in patients with AF, with oral anticoagulants (OACs) being generally recommended for those 
with a CHA2DS2-VASc score of ≥ 2.9 However, lifelong OAC therapy to prevent stroke is 
recommended in HCM patients who develop AF regardless of the patient’s CHA2DS2-VASc 
score.9-11 Non–vitamin K antagonist oral anticoagulants (NOACs) may be reasonable 
alternatives to warfarin, but there are limited data to support their use, since few patients with 
HCM were included in existing NOACs trials.11,12 Therefore, large observational studies may 
offer an opportunity to examine the effectiveness and safety outcomes of NOAC use in these 
patients. In this nationwide cohort study, we sought to describe the pattern of use, occurrence 
of thromboembolic events and bleeding, and mortality in patients with HCM and AF treated 
with NOACs. 
 
Materials and Methods 
This study is based on the national health claims database established by the National 
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Health Insurance Service (NHIS) of the Republic of Korea.2,3,13 Details of Korean NHIS 
database are summarized in e-Appendix 1. This study was approved by the Institutional 
Review Board of the Yonsei University Health System (4-2016-0179), and informed consent 
was waived. 
 
Study population 
From the Korean NHIS database, 10,020 patients with HCM and AF who were aged 
18 years or older were identified during the period from January 1, 2011 to December 31, 
2016. The following were exclusion criteria: (i) those with valvular AF, such as mitral valve 
stenosis or prosthetic valve disease (n=576), (ii) those who had undergone radiofrequency 
ablation for AF (n=239), (iii) those with end-stage renal disease (n=97), (iv) those with no 
OAC use during the study period (Jan 2011 to Dec 2016) (n=3,667), (v) those with OAC use 
of less than 30 days (n=1,821), and (vi) those with OAC use for acute coronary syndrome or 
deep vein thrombosis prophylaxis (n=130). Finally, a total of 3,490 patients who took 
warfarin (n=1,188) or NOACs (n=2,302) were enrolled (Fig 1). After propensity score (PS) 
matching, we identified a warfarin-treated group of patients with HCM and AF (n=958) who 
were compared with a 1:2 propensity-matched NOAC treated group (n=1,514). 
AF was diagnosed using the International Classification of Disease 10th Revision 
(ICD-10) codes I48, I48.0, and I48.1. Moreover, patients were defined as having AF only 
when they were given AF as a discharge diagnosis, or when this diagnosis was confirmed 
more than twice in the outpatient department, to ensure diagnostic accuracy. ICD-10 codes 
were used when diagnosing HCM (I42.1, I42.2) and obstructive HCM (I42.1). The validation 
of AF and HCM diagnosis is summarized in e-Appendix 1.  
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Baseline comorbidities and outcome events 
Comorbidities were defined according to ICD-10 codes, prescription medication use 
using medical claim records. The definitions of comorbidities are presented in e-Table 1. The 
presence of comorbidities was assessed at the time of OAC initiation. 
Primary outcome events were the first occurrence of all-cause death, any ischemic 
stroke, major bleeding, and any acute myocardial infarction (MI). Secondary outcome events 
were the occurrence of fatal ischemic stroke, fatal bleeding, fatal acute MI, and the composite 
of these fatal cardiovascular events. Any event that led to death within one month of its 
occurrence was considered a fatal event. Detailed information on outcomes is summarized in 
e-Appendix 1. 
 
Statistical analysis 
The detailed methods of statistical analysis are described in e-Appendix 1. 
 
 
Results 
Within the NOAC group (n=2,302), 890 patients were receiving rivaroxaban (38.7%), 
705 dabigatran (30.6%), 585 apixaban (25.4%), and 122 edoxaban (5.3%). Table 1 shows the 
baseline characteristics of the study population before and after PS-matching. Before PS-
matching, 55% of the NOAC group were male (vs. 57% in the warfarin group; p=0.32) and 
the mean age was higher in the NOAC group compared with the warfarin group (70.9 ± 10.2 
vs. 67.0 ± 12.5 years; p<0.001). All comorbidities, including previous transient ischemic 
attack / ischemic stroke, hemorrhagic stroke, atherosclerotic disease, hypertension, diabetes, 
heart failure, malignant neoplasm, chronic kidney disease, dyslipidemia and chronic 
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obstructive pulmonary disease, were more prevalent in patients on NOACs than in those on 
warfarin (all p<0.05). e-Table 2 shows that the baseline medications were also different 
between the two groups, with a higher use of antiplatelet therapy (aspirin or P2Y12 inhibitor) 
in the warfarin group (all p<0.05). Covariates had significant imbalances in the pre-matched 
cohort but were well balanced after PS-matching. Absolute standardized mean differences in 
all measured covariates were less than 0.1, suggesting substantial covariate balance across the 
groups after PS-matching. 
 
Primary outcome events 
During a median follow-up of 16 months (interquartile range: 8-24 months), when 
considering the NOAC and warfarin groups together before PS-matching, ischemic stroke / 
systemic embolism and major bleeding occurred in 9.7% (339 of 3,490) and 6.3% (219 of 
3,490) of AF patients with HCM, respectively. Overall, 315 out of 3,490 patients (9.0%) died. 
(e-Table 3). 
In the PS-matched groups, the incidence rates for ischemic stroke or systemic 
embolism were similar between NOAC- and warfarin-treated patients (8.33 vs. 7.96 events 
per 100 person-years, respectively; p=0.725) (Fig 2). Major bleeding, gastrointestinal 
bleeding, intracranial hemorrhage, and acute MI were also similar between NOAC- and 
warfarin-treated patients. The incidence rate for all-cause death was significantly lower in 
NOAC-treated than in warfarin-treated patients (5.11 vs. 10.13 events per 100 person-years, 
respectively; p<0.001). Compared with warfarin, use of NOACs was associated with a 
significantly lower risk of all cause-mortality (HR) of 0.43 (95% confidence interval [CI]: 
0.32-0.57; p<0.001) (Fig 2). Both standard- (HR 0.40; 95% CI 0.27-0.60) and reduced-dose 
NOACs (HR 0.45; 95% CI 0.32-0.63) were associated with significantly lower risk of all-
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cause mortality with reference to warfarin (e-Table 4). 
Fig 3 shows the Kaplan–Meier curves for clinical events in NOAC- and warfarin-
treated patients after PS-matching. NOAC use was associated with significantly better event 
free survival from all-cause death than warfarin-treated patients (log-rank p<0.001). 
 
Secondary outcome events 
We compared the fatal cardiovascular events between PS-matched NOAC- and 
warfarin-treated patients. The incidence rates of fatal ischemic stroke (0.40 vs 0.48 events per 
100 person-years, respectively; HR 0.87; 95% CI: 0.25-2.98, p=0.819) were similar between 
NOAC- and warfarin-treated patients. However, use of NOACs was associated with lower 
risks of fatal bleeding (0.33 vs 1.02 events per 100 person-years, respectively; HR 0.33; 95% 
CI: 0.11-0.99, p=0.047) and fatal MI (0.06 vs 0.39 events per 100 person-years, respectively; 
HR 0.06; 95% CI: 0.00-0.92, p=0.043) compared to warfarin-treated patients. 
Consequentially, the incidence rate for the composite of these fatal cardiovascular events was 
significantly lower in NOAC-treated patients compared to warfarin-treated patients (0.77 vs. 
1.80 events per 100 person-years, respectively; HR: 0.39; 95% CI: 0.18-0.82; p=0.013) (Fig 
4).  
Fig 5 shows the Kaplan–Meier curves for fatal clinical events in NOAC-treated and 
warfarin-treated patients. NOAC was associated with significantly better event free survival 
from fatal bleeding (log-rank p=0.023), fatal MI (log-rank p=0.037) and composite fatal 
cardiovascular events (log-rank p=0.010) than warfarin.  
 
Subgroup analysis 
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The mortality benefit of NOACs compared to warfarin in AF patients with HCM was 
consistent across most subgroups although it could not be assessed in patients with 
CHA2DS2-VASc scores ≤ 1 or in those without hypertension because of the small number of 
subjects (Fig 6). Compared with warfarin, use of NOAC was associated with significantly 
lower risk of all-cause mortality, regardless of sex, heart failure, diabetes mellitus previous 
transient ischemic attack / ischemic stroke, and CKD. NOACs were associated with a 
significantly lower all-cause mortality than warfarin in those aged ≥ 65 years, those without 
previous MI, those with dyslipidemia, those with non-obstructive HCM, those with 
CHA2DS2-VASc score ≥ 2 and those with hypertension. 
 There was no significant difference in the number of events, incidence, and risk of 
various events among apixaban, dabigatran and rivaroxaban in AF patients with HCM (e-
Table 5). 
 
Discussion 
The principal finding of this study was that the incidences of stroke or major 
bleeding were similar between NOAC- and warfarin-treated AF patients with HCM. Second, 
use of NOAC was associated with significantly lower all-cause mortality than warfarin. 
Moreover, the composite of fatal cardiovascular events was lower amongst NOAC-treated 
patients, compared to warfarin-treated patients. The lower all-cause mortality in NOAC-
treated patients was evident across most subgroups. Our data suggest that AF patients with 
HCM can be safely and effectively treated with NOACs. 
 
Oral anticoagulant for in AF patients with HCM 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
AF is the most common arrhythmia in patients with HCM. Prospective data show 
that after 10 years of follow-up, 22% to 30% of HCM patients develop AF.4,5,14 AF has a 
strong impact on the clinical course of HCM and on patients' quality of life. Due to the very 
high embolic risk, life-long OAC treatment is recommended in all HCM patients with AF. 
This recommendation is based on observational studies showing that warfarin-treated HCM 
patients with AF presented with about one half the number of embolic events (18% vs. 31%, 
respectively) and strokes (10% vs. 39%, respectively) compared to those not receiving OAC 
treatment.4  
While HCM patients were not formally excluded from NOAC trials, the number of 
HCM patients included in these studies is unknown, and was presumably low because these 
patients tend to be younger (the mean age of patients included in NOAC trials was >70 years) 
and often do not exhibit the traditional CHADS2 factors required to participate in NOAC 
studies. Therefore, few data currently support the use of NOACs in patients with HCM and 
AF despite the notion that NOACs could represent a valid alternative to warfarin treatment in 
this younger, active population. 
The latest guidelines state that NOACs are broadly preferable to warfarin in the vast 
majority of patients with non-valvular AF,9 based on clinical trials that have shown 
equivalent efficacy compared with warfarin, as well as better safety and a lower occurrence 
of intracranial hemorrhage.15 Furthermore, recent studies have observed that NOACs are 
more cost effective than adjusted dose warfarin,16 and that non-valvular AF patients are 
generally more satisfied with medical care when treated with NOACs.  
The comparison of comorbidities and outcome events with other studies is discussed 
in e-Appendix 2.  
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NOACs, mortality, and fatal outcomes  
The annual rates of ischemic stroke, systemic embolism, or major bleeding were 
similar between NOAC- and warfarin-treated patients. Our data show that usage of NOACs 
was associated with significantly lower all-cause mortality compared with warfarin, 
especially by reducing the composite of fatal cardiovascular events. In prior randomized 
clinical trials of NOAC vs. warfarin, there was no reduction in mortality except in apixaban 
trial. However, in Danish nationwide databases, the annual risk of death was significantly 
lower with apixaban and dabigatran compared with warfarin.17 In real-world data from 
Asians with non-valvular AF, NOACs were associated with reduced risk for all-cause 
mortality compared to warfarin.18 This finding was well explained by lower risk of composite 
of fatal cardiovascular events associated with NOAC use in this study.  
A recent studies suggested that patients with HCM and AF could be safely treated 
with NOACs.12,19 However, these studies were probably underpowered in terms of the 
number of individuals needed to concretely demonstrate the superiority of NOACs over 
warfarin in patients with HCM and AF. The results of our study, which used the largest 
sample of subjects with HCM published thus far, favor the use of NOACs as an alternative to 
warfarin when OAC treatment is needed for patients with HCM and AF.  
In the subgroup analyses, the mortality reduction associated with NOAC treatment 
was observed across most subgroups. The prevalence of hypertension was over 95% in both 
PS-matched NOAC- and warfarin-treated groups. Because NOAC treatment is fully 
reimbursed only in Korean AF patients with CHA2DS2-VASc scores ≥ 2, the number of 
patients using NOACs was low amongst those with CHA2DS2-VASc scores ≤ 1. Therefore, 
the benefit of NOAC treatment was not adequately assessed in patients with CHA2DS2-VASc 
scores ≤ 1, and in those without hypertension. 
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Major and GI bleeding was more prevalent in reduced dose NOAC than standard 
dose users. This finding is consistent with previous studies.20,21 In real-world studies, the 
choice of dosage of NOAC was obviously not due to random chance, but rather a complex 
mixture of physician experience, patient preferences, and clinical characteristics.  
 
Study limitations 
The present study has several limitations. Although administrative databases are 
increasingly used for clinical research, studies using such databases are potentially 
susceptible to errors arising from coding inaccuracies. To minimize this problem, we applied 
the definitions that we had already validated in previous studies that used a Korean NHIS 
sample cohort.2,3,22 Although we validated the accuracy of our definition of HCM, we cannot 
exclude the possibility that hypertensive heart disease was included in our study population. 
Second, we were unable to define the type of AF (paroxysmal vs. persistent) in this study. In 
addition, we relied on billing codes for determination of patient characteristics and outcomes. 
As such, we lacked data on clinical characteristics, such as mitral valve dysfunction, left 
atrial enlargement, left ventricular dysfunction, and other factors that may predispose patients 
to cardioembolism. The information on family history of HCM and family history of sudden 
death was also unavailable. Third, more than half the NOAC treated patients in this study 
were receiving reduced doses of NOACs. This finding is consistent with the previous study 
that Asian physicians tend to prescribe low-dose NOACs to patients with AF for a number of 
reasons including the lower average body mass index of Asian adults and the concern for 
higher risk of ICH.23 Finally, we had no data on time in therapeutic range (TTR) for the 
warfarin group due to the limitations of the national health claim database. Poor TTR status 
has generally been observed in Asian cohorts,24,25 and may have affected the favorable 
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mortality outcomes seen in the NOAC group. A single-center study in which warfarin therapy 
was managed by a formal anticoagulation clinic showed that the TTR in AF-related stroke 
patients was 57.5%.26 A recent multicentre retrospective study reported that the mean TTR of 
individual patients was 49.1% in Korean AF patients.27 
Nonetheless, these observational data provide a glimpse of real-world clinical 
outcomes associated with NOAC use in patients with HCM and AF, a group not well studied 
in previously published or ongoing clinical trials. 
 
Conclusions 
Compared with those on warfarin, AF patients with HCM on NOACs had similar stroke and 
major bleeding risks, but was associated with lower all-cause mortality and the composite of 
fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely 
and effectively treated with NOACs. 
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Table 1. Baseline characteristics before and after propensity score matching by treatment 
group (NOAC vs. warfarin). 
 Before propensity score matching After propensity score matching 
 Warfarin 
(n = 1,188) 
NOAC 
(n = 2,302) ASMD 
Warfarin 
(n = 955) 
NOAC 
(n = 1,504) ASMD 
Age, years 67.0 ± 12.5 70.9 ± 10.2 0.336 68.6 ± 11.6 69.3 ± 10.5 0.067 
<65 444 (37.4) 545 (23.7) 
 
314 (32.9) 438 (29.1)  
65-74 385 (32.4) 795 (34.5) 
 
316 (33.1) 524 (34.8)  
≥75 359 (30.2) 962 (41.8) 
 
325 (34.0) 542 (36.0)  
Men 675 (56.8) 1,267 (55.0) 0.036 530 (55.5) 838 (55.7) 0.004 
CHA2DS2-VASc 
score 
4.36 ± 2.14 5.20 ± 1.84 0.419 4.67 ± 2.08 4.82 ± 1.84 0.079 
Previous ischemic 
stroke / TIA 480 (40.4) 1,262 (54.8) 0.292 437 (45.8) 728 (48.4) 0.053 
Previous 
hemorrhagic stroke 38 (3.2) 120 (5.2) 0.100 30 (3.1) 63 (4.2) 0.056 
Previous MI 237 (19.9) 497 (21.6) 0.040 204 (21.4) 320 (21.3) 0.002 
PAD 218 (18.4) 537 (23.3) 0.123 199 (20.8) 307 (20.4) 0.011 
Vascular disease 402 (33.8) 879 (38.2) 0.091 353 (37.0) 541 (36.0) 0.021 
Hypertension 1,078 (90.7) 2,247 (97.6) 0.273 909 (95.2) 1,452 (96.5) 0.068 
Diabetes mellitus 339 (28.5) 784 (34.0) 0.119 290 (30.4) 463 (30.8) 0.009 
Heart failure 740 (62.3) 1,755 (76.2) 0.306 641 (67.1) 1,069 (71.1) 0.086 
History of cancer 301 (25.3) 747 (32.5) 0.157 263 (27.5) 435 (28.9) 0.031 
CKD 128 (10.8) 281 (12.2) 0.045 109 (11.4) 171 (11.4) 0.001 
Dyslipidemia 1,032 (86.9) 2,176 (94.5) 0.266 864 (90.5) 1,387 (92.2) 0.062 
COPD 475 (40.0) 1042 (45.3) 0.107 408 (42.7) 652 (43.4) 0.013 
Obstructive HCM 191 (16.1) 327 (14.2) 0.053 154 (16.1) 210 (14.0) 0.061 
Values are expressed as n (%) or mean ± SD. ASMD = absolute standardized mean diﬀerence; 
CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; HCM = 
hypertrophic cardiomyopathy; MI = myocardial infarction; NOAC = non–vitamin K 
antagonist oral anticoagulant; PAD = peripheral artery disease; TIA = transient ischemic 
attack; Vascular disease = previous MI, PAD, or aortic plaque. 
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Figure legends  
Figure 1. Flowchart of study population. ACS = acute coronary syndrome; AF = atrial 
fibrillation; DVT = deep vein thrombosis; ESRD = end-stage renal disease; HCM = 
hypertrophic cardiomyopathy; NOAC = non–vitamin K antagonist oral anticoagulant; OAC = 
oral anticoagulant; RFCA = radiofrequency catheter ablation. 
 
Figure 2. The number of events, incidence, and risk of primary outcomes in propensity score 
matched NOAC- and warfarin-treated patients with HCM and AF. CI = confidence interval. 
Other abbreviations are as in Figure 1. 
 
Figure 3. Kaplan-Meier curves for the crude cumulative incidence of primary outcomes. (A) 
Ischemic stroke, (B) major bleeding, (C) acute myocardial infarction, and (D) all-cause death 
in propensity score matched warfarin- and NOAC-treated patients with HCM and AF. 
NOAC-treated patients showed significantly better event free survival from all-cause death 
than warfarin-treated patients. Abbreviations are as in Figure 1. 
 
Figure 4. The number of events, incidence, and risk of fatal cardiovascular events in 
propensity score matched NOAC- and warfarin-treated patients with HCM and AF. CI = 
confidence interval. Other abbreviations are as in Figure 1. 
 
Figure 5. Kaplan–Meier curves for fatal cardiovascular events. (A) Fatal ischemic stroke, (B) 
fatal bleeding, (C) fatal acute MI, and (D) composite of these fatal cardiovascular events in 
propensity score matched NOAC- and warfarin-treated patients with HCM and AF. A fatal 
event is defined as an event in which the patient dies within 30 days of the event. MI = 
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myocardial infarction. Other abbreviations are as in Figure 1. 
 
Figure 6. Forest plot displaying the hazard ratio for all-cause death for the NOAC-treated 
patients with HCM and AF compared with the warfarin-treated patients among various 
subgroups. CI = confidence interval; TIA = transient ischemic attack. Other abbreviations are 
as in Figure 1. 
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for stroke prevention from Jan 2011 –
Dec 2016 (n = 3,490)
Excluded patients (n = 6,530)
- With valvular AF (n = 576)
- Who had undergone RFCA (n = 239)
- Who were diagnosed with ESRD (n = 97)
- Who did not use OACs during the study period 
(Jan 2011 to Dec 2016) (n = 3,667)
- Who used OACs for less than 30 days (n = 1,821)
- Who used OACs for ACS or DVT prophylaxis (n = 
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AF patients with HCM diagnosed 
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Warfarin
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Patients, n Events, n Incidence (95% CI) Hazard ratio* (95% CI) p-value
Death from all causes
Warfarin 955 158 10.13 (8.61-11.83) Reference -
NOAC 1,504 80 5.11 (4.05-6.36) 0.43 (0.32-0.57) <0.001
Ischemic stroke or systemic embolism
Warfarin 955 115 7.96 (6.57-9.55) Reference -
NOAC 1,504 124 8.33 (6.93-9.93) 0.94 (0.72-1.23) 0.672
Major bleeding
Warfarin 955 78 5.19 (4.11-6.48) Reference -
NOAC 1,504 82 5.41 (4.30-6.71) 0.97 (0.70-1.34) 0.838
GI bleeding
Warfarin 955 61 4.03 (3.08-5.17) Reference -
NOAC 1,504 67 4.40 (3.41-5.59) 0.99 (0.69-1.44) 0.985
Intracranial hemorrhage
Warfarin 955 14 0.90 (0.49-1.51) Reference -
NOAC 1,504 10 0.64 (0.31-1.18) 0.70 (0.29-1.68) 0.421
Acute myocardial infarction
Warfarin 955 31 2.01 (1.37-2.86) Reference -
NOAC 1,504 44 2.85 (2.07-3.83) 1.32 (0.81-2.16) 0.263
Figure 2.
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Patients, n Events, n Incidence (95% CI) Hazard ratio* (95% CI) p-value
Fatal ischemic stroke
Warfarin 955 7 0.48 (0.19-0.98) Reference -
NOAC 1,504 6 0.40 (0.15-0.87) 0.87 (0.25-2.98) 0.819
Fatal bleeding
Warfarin 955 15 1.02 (0.57-1.69) Reference -
NOAC 1,504 5 0.33 (0.11-0.78) 0.33 (0.11-0.99) 0.047
Fatal acute myocardial infarction
Warfarin 955 6 0.39 (0.14-0.85) Reference -
NOAC 1,504 1 0.06 (0.00-0.36) 0.06 (0.00-0.92) 0.043
Composite of fatal cardiovascular events
Warfarin 955 25 1.80 (1.17-2.66) Reference -
NOAC 1,504 11 0.77 (0.38-1.38) 0.39 (0.18-0.82) 0.013
Figure 4.
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Figure 6. Hazard ratio* (95% CI) for all-cause death p forinteraction
Age, years
<65 (n= 752) 0.54 (0.22-1.33)
0.73965-74 (n=840) 0.42 (0.25-0.72)
≥75 (n=867) 0.48 (0.34-0.68)
Sex
Male (n=1,368) 0.52 (0.34-0.78)
0.726
Female (n=1,091) 0.49 (0.33-0.71)
CHA2DS2-VASc score
0-1 (n=100) 0.03 (0-3.3E6)
0.943
≥2 (n=2,359) 0.47 (0.36-0.62)
Heart failure
Yes (n=1,710) 0.53 (0.39-0.72)
0.369
No (n=749) 0.34 (0.17-0.66)
Hypertension
Yes (n=2,361) 0.51 (0.39-0.68)
0.932
No (n=98) 0.02 (0-11.21)
Diabetes mellitus
Yes (n=753) 0.54 (0.34-0.85)
0.684
No (n=1,706) 0.47 (0.34-0.67)
Previous Ischemic stroke / TIA
Yes (n=1,165) 0.47 (0.33-0.67)
0.772
No (n=1,294) 0.52 (0.34-0.80)
Previous myocardial infarction
Yes (n=524) 0.64 (0.39-1.03)
0.245
No (n=1,935) 0.44 (0.31-0.62)
Chronic kidney disease
Yes (n=280) 0.46 (0.22-0.95)
0.942
No (n=2,179) 0.50 (0.37-0.67)
Dyslipidemia
Yes (n=2,251) 0.51 (0.38-0.68)
0.680
No (n=208) 0.43 (0.18-1.02)
Obstructive HCM
Yes (n=364) 0.53 (0.26-1.08)
0.817
No (n=2,095) 0.49 (0.36-0.66)
NOAC 
better
Warfarin 
better0.0 0.5 1.0 1.5
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e-Appendix 1.  
Methods 
Database Description 
The National Health Insurance Service (NHIS) is a single insurer managed by the 
Korean government, and the majority (97.1%) of the Korean population are mandatory 
subscribers, with the remaining 3% of the population being medical aid subjects. The NHIS 
database also contains information on the medical aid subjects, and is therefore based on the 
entire Korean population.1 The following medical information is provided: the patients’ 
sociodemographic information, their use of inpatient and outpatient services, their pharmacy 
dispensing claims, and mortality data. Every person in the NHIS database is linked to their 
information by their Korean social security numbers. In this study, all social security numbers 
were deleted after constructing the cohort by assigning each individual a serial number to 
prevent the leakage of personal information. These databases are open to researchers, whose 
study protocols are approved by the official review committee. 
 
Outcome events 
Primary outcome events were the first occurrence of all-cause death, any ischemic 
stroke, major bleeding, and any acute myocardial infarction (MI). The mortality information 
along with date of death of the participants was included in NHIS database, obtained from 
the Korean National Statistical Office. Ischemic stroke was defined as any admission diagnosis 
of ischemic stroke (ICD-10 codes: I63, I64) with concomitant brain-imaging studies, including 
computed tomography or magnetic resonance imaging. The definition of ischemic stroke was 
validated in previous studies.2-4 Major bleeding was defined as gastrointestinal bleeding (ICD-
10 codes: K25-28 [subcodes 0-2 and 4-6 only], K92.0, K92.1, K92.2, K62.5, I85.0, I98.3) or 
a cerebral hemorrhage episode (ICD-10 codes: I60-I62) that required hospital admission 
and/or a blood transfusion. Acute MI was identified by any admission diagnosis of acute MI 
(ICD-10 codes: I21, I22) with prescription of dual antiplatelet therapy of aspirin and P2Y12 
inhibitor during admission. The definition of acute MI was also validated in previous study.5 
 
Validation of diagnosis 
In Korea, hypertrophic cardiomyopathy (HCM) patients are registered in the national 
registry for rare diseases and can receive large medical expense reductions. Therefore, HCM 
diagnostic code entry is very strictly controlled. To evaluate the accuracy of our definition of 
HCM, we conducted a validation study in two hospitals with 2,970 patients with the ICD-10 
code (I42.1, I42.2). The patients’ medical records and images including echocardiography 
were reviewed by two physicians (PSY and BYJ). Patients were ascertained to have HCM if it 
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was diagnosed by echocardiography and registered in the national registry for rare diseases 
to get insurance benefits. The positive predictive value was 90.7%. The diagnosis of AF has 
previously been validated in the NHIS database, with a positive predictive value of 94.1%.2,3,6 
 
Statistical analysis 
Descriptive statistics were used to characterize baseline characteristics and 
comorbidities. Continuous variables were expressed as the means ± standard deviations and 
categorical variables were reported as frequencies (percentages). We created a propensity 
score (PS)–matched warfarin versus non–vitamin K antagonist oral anticoagulants (NOACs) 
cohort, using 1:2 PS matching without replacement and with a caliper of 0.1 based on baseline 
characteristics, including age, sex, annual household income, individual components of the 
CHA2DS22-VASc scores, history of cerebral hemorrhage, chronic kidney disease, chronic 
obstructive pulmonary disease, dyslipidemia and obstructive hypertrophic cardiomyopathy. 
We used Cox proportional hazards models to compare time to outcome events between 
groups. A multivariate-adjusted analysis was performed after adjusting for age, sex, 
hypertension, previous transient ischemic attack / ischemic stroke, previous hemorrhagic 
stroke, previous vascular disease, diabetes mellitus, heart failure, history of malignant 
neoplasm, chronic kidney disease, dyslipidemia, chronic obstructive pulmonary disease, 
obstructive hypertrophic cardiomyopathy, implantable cardioverter-defibrillator insertion, 
surgical myectomy and usage of medications including aspirin, P2Y12 inhibitor, statin, beta 
blocker, angiotensin converting enzyme inhibitor / angiotensin receptor blocker, diuretics, 
dihydropyridine calcium channel blocker, non-dihydropyridine calcium channel blocker, 
digoxin, class Ic antiarrhythmic drugs, amiodarone, dronedarone, rifampin, phenytoin, azole 
based antifungal agents and proton pump inhibitors. The patients were censored at the date 
when the endpoint events occurred, at the date of their death, or at end of follow-up. All tests 
were two-tailed, with a p-value of <0.05 considered significant. Statistical analyses were 
conducted with SAS version 9.3 (SAS Institute, Cary, NC, USA) and the SPSS version 23.0 
statistical package (SPSS Inc., Chicago, IL, USA). 
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e-Appendix 2.  
Discussion 
Comorbidities and outcome events  
Because this study included only HCM patients on OAC, the direct comparison of 
comorbidities with other studies which included overall HCM patients is impossible. he high 
prevalence of comorbidities including hypertension and heart failure in HCM with OAC might 
be related to the fact that this study only included HCM with AF taking OAC. Although the 
prevalence of hypertension was above 90% in this study, it was only 68% in HCM without AF 
(e-Table 6). Moreover, because NOAC is not reimbursed in Korean AF patients with CHA2DS2-
VASc scores less than 2, the NOAC group had even more stroke related comorbidities. Third, 
the mean age of HCM patients of this study was consistent with a large U.S. commercial 
insurance database,7 but was older than those without AF in the Mayo Clinic report.8   
Moreover, although the all-cause death in this study was around 12% at 1 year in 
warfarin treated patients, the incidence of all-cause death was 4.2% in overall patients with 
HCM with AF. This number was actually lower compared with the annual mortality rates of 
patients with HCM and AF in the Mayo Clinic series (6.9%).8 Good anticoagulation control is 
associated with reductions in stroke and mortality in AF patients. If warfarin control is 
suboptimal this may be a contributory factor. 
The stroke and bleeding rates in this study were higher or comparable with those 
found in the NOAC trials.9,10 The rate of ischemic stroke/systemic embolism of Korean AF is 
reported 3.98 per 100 Person-Years. This rate is similar to the Denmark Nationwide Cohort 
of 5.29 per 100 Person-Years and is much higher than Euro Heart Survey of 2.3 per 100 
Person-Years.3,11 It is well known that individuals of Asian ethnicity are at a disproportionately 
high risk of stroke and have greater consequent mortality.12 Moreover, the HCM patients with 
AF had higher risk of stroke compared to non-HCM AF patients. Even AF patients with HCM 
who were categorized as ‘low risk’ have an unadjusted rate of ischemic stroke of 3.38%.13 
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e-Table 1. Definitions and ICD-10 codes used for defining comorbidities. 
Comorbidity Definition ICD-10 code or condition 
Heart failure Defined from diagnosis a ICD-10: I11.0, I50, I97.1 
Hypertension 
Defined from diagnosis a plus 
treatment 
ICD-10: I10, I11, I12, I13, I15 
Treatment: beta-blocker, ACEi, ARB, DHP CCB or diuretics 
Diabetes mellitus 
Defined from diagnosis a plus 
treatment 
ICD-10: E10, E11, E12, E13, E14 
Treatment: all kinds of oral antidiabetics and insulin 
Ischemic stroke Defined from diagnosis a ICD-10: I63, I64 
TIA Defined from diagnosis a ICD-10: G45 
Previous MI Defined from diagnosis a ICD-10: I21, I22, I25.2 
Peripheral arterial disease Defined from diagnosis a ICD-10: I70.0, I70.1, I70.2, I70.8, I70.9 
CKD Defined from diagnosis a ICD-10: N18, N19 
ESRD 
Defined from the national registry 
for severe illness. 
Patients undergoing chronic dialysis or those who had received a kidney 
transplant. 
Dyslipidemia Defined from diagnosis a ICD-10: E78 
Malignancy 
Defined from diagnoses of cancer 
(non-benign) 
ICD-10: C00-C97 
COPD 
Defined from diagnosis a plus 
treatment 
ICD-10: J42, J43(except J43.0), J44 
Treatment: inhaled corticosteroid, inhaled bronchodilators, or oral 
methylxanthine (>1 months). 
ACEi = Angiotensin Converting Enzyme inhibitor; ARB = Angiotensin Receptor Blocker; DHP = Dihydropyridine; CCB = Calcium Channel 
Blocker; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; ESRD = end stage renal disease; eGFR = estimated 
glomerular filtration rate; MI = myocardial infarction; TIA = transient ischemic attack. 
a To ensure accuracy, comorbidities were established based on more than one inpatient or two outpatient records of ICD-10 codes in the 
database. 
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e-Table 2. Prescription rate of medications before and after propensity score matching. 
 
Before propensity score 
matching 
After propensity score matching 
 Warfarin 
(n = 
1,188) 
NOAC 
(n = 
2,302) 
p-
value 
Warfarin 
(n = 955) 
NOAC 
(n = 
1,504) 
p-value 
Aspirin 492 (41.4) 381 (16.6) <0.001 321 (33.6) 374 (24.9) <0.001 
P2Y12 inhibitor 235 (19.8) 243 (10.6) <0.001 160 (16.8) 198 (13.2) <0.001 
Statin 680 (57.2) 1383 (60.1) 0.002 560 (58.6) 879 (58.4) 0.848 
Beta blocker 890 (74.9) 1555 (67.5) <0.001 712 (74.6) 
1,047(69.6
) 
<0.001 
ACEi / ARB 696 (58.6) 1241 (53.9) <0.001 554 (58.0) 828 (55.1) 0.003 
Diuretics 775 (65.2) 1359 (59.0) <0.001 633 (66.3) 856 (56.9) <0.001 
Potassium 
sparing diuretics 
380 (32.0) 609 (26.5) <0.001 314 (32.9) 386 (25.7) <0.001 
DHP CCB 307 (25.8) 444 (19.3) <0.001 243 (25.4) 280 (18.6) <0.001 
Non-DHP CCB 290 (24.4) 461 (20.0) <0.001 228 (23.9) 308 (20.5) <0.001 
Verapamil 66 (5.6) 124 (5.4) 0.677 61 (6.4) 76 (5.1) 0.005 
AAD Ic 81 (6.8) 142 (6.2) 0.138 62 (6.5) 93 (6.2) 0.540 
AAD III 364 (30.6) 484 (21.0) <0.001 282 (29.5) 356 (23.7) <0.001 
Amiodarone 333 (28.0) 428 (18.6) <0.001 258 (27.0) 317 (21.1) <0.001 
Dronedarone 34 (2.9) 53 (2.3) 0.045 28 (2.9) 36 (2.4) 0.103 
Digoxin 220 (18.5) 377 (16.4) 0.002 185 (19.4) 231 (15.4) <0.001 
Rifampin 11 (0.9) 13 (0.6) 0.014 11 (1.2) 9 (0.6) 0.003 
Phenytoin 3 (0.3) 6 (0.3) 0.929 2 (0.2) 3 (0.2) 0.915 
Azole antifungals 26 (2.2) 29 (1.3) <0.001 19 (2.0) 19 (1.3) 0.004 
PPI 483 (40.7) 856 (37.2) <0.001 396 (41.5) 561 (37.3) <0.001 
ICD implantation 49 (4.1) 84 (3.6) 0.487 37 (4.0) 60 (4.0) 0.775 
Surgical myectomy 20 (1.7) 6 (0.3) <0.001 17 (1.8) 5 (0.3) <0.001 
Septal alcohol 
ablation 
0 0  0 0  
Values are expressed as n (%) or mean ± SD. ACEi = Angiotensin Converting Enzyme inhibitor; 
ARB = Angiotensin Receptor Blocker; DHP = Dihydropyridine; CCB = Calcium Channel Blocker; 
AAD = Antiarrhythmic Drug; PPI = Proton Pump Inhibitor, ICD = Implantable Cardioverter-
Defibrillator 
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e-Table 3. The number of events, incidence, and risk of various events in NOAC- and warfarin-
treated AF patients with HCM among baseline study population before propensity score matching. 
 
Warfarin 
(n = 1,188) 
NOAC 
(n = 2,302) 
p value 
Death from all causes     
Number of events 182 133  
Incidence per 100 person-years (95% CI) 9.37 (8.06-10.83) 5.66 (4.74-6.71) <0.001 
Hazard ratio a Reference 0.40 (0.31-0.51) <0.001 
Ischemic stroke or systemic embolism    
Number of events 144 195  
Incidence per 100 person-years (95% CI) 8.03 (6.77-9.46) 8.71 (7.53-10.02) 0.461 
Hazard ratio a Reference 0.95 (0.75-1.22) 0.700 
Major bleeding    
Number of events 98 121  
Incidence per 100 person-years (95% CI) 5.23 (4.25-6.38) 5.31 (4.40-6.34) 0.918 
Hazard ratio a Reference 0.95 (0.70-1.29) 0.736 
Gastrointestinal bleeding    
Number of events 73 98  
Incidence per 100 person-years (95% CI) 3.86 (3.03-4.86) 4.28 (3.48-5.22) 0.506 
Hazard ratio a Reference 1.01 (0.71-1.42) 0.972 
Intracranial hemorrhage    
Number of events 18 19  
Incidence per 100 person-years (95% CI) 0.93 (0.55-1.47) 0.81 (0.49-1.27) 0.674 
Hazard ratio a Reference 0.86 (0.41-1.82) 0.698 
Acute myocardial infarction    
Number of events 36 55  
Incidence per 100 person-years (95% CI) 1.88 (1.32-2.60) 2.37 (1.78-3.08) 0.280 
Hazard ratio a Reference 1.28 (0.80-2.06) 0.303 
Composite fatal cardiovascular events    
Number of events 32 20  
Incidence per 100 person-years (95% CI) 1.86 (1.27-2.62) 0.92 (0.56-1.43) 0.013 
Hazard ratio a Reference 0.34 (0.19-0.64) 0.001 
AF = atrial fibrillation; CI = confidence interval; HCM = hypertrophic cardiomyopathy; NOAC = 
Non–vitamin K antagonist oral anticoagulants. 
a Multivariate-adjusted for age, sex, heart failure, hypertension, diabetes mellitus, previous 
transient ischemic attack / ischemic stroke, previous hemorrhagic stroke, previous vascular 
disease, malignant neoplasm, chronic kidney disease, dyslipidemia, chronic obstructive pulmonary 
disease, obstructive hypertrophic cardiomyopathy, implantable cardioverter-defibrillator insertion, 
surgical myectomy and medications (aspirin, P2Y12 inhibitor, statin, beta blocker, angiotensin 
converting enzyme inhibitor / angiotensin receptor blocker, diuretics, dihydropyridine calcium 
channel blocker, non-dihydropyridine calcium channel blocker, digoxin, class Ic antiarrhythmic 
drugs, amiodarone, dronedarone, rifampin, phenytoin, azole based antifungal agents and proton 
pump inhibitor). 
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e-Table 4. The number of events, incidence, and risk of various events in patients with HCM and AF according to NOAC dose after propensity 
score matching. 
  Warfarin Reduced dose NOAC Standard dose NOAC 
  (n =955) (n=751) (n=753) 
Death from all causes    
Number of events 158 49 31 
Incidence per 100 person-years (95% CI) 10.13 (8.61-11.83) 6.44 (4.77-8.52) 3.85 (2.62-5.47) 
Hazard ratio a Reference 0.45 (0.32-0.63) 0.40 (0.27-0.60) 
Ischemic stroke or systemic embolism    
Number of events 115 58 66 
Incidence per 100 person-years (95% CI) 7.96 (6.57-9.55) 7.97 (6.05-10.30) 8.67 (6.71-11.04) 
Hazard ratio a Reference 0.84 (0.60-1.17) 1.06 (0.77-1.45) 
Major bleeding    
Number of events 78 45 37 
Incidence per 100 person-years (95% CI) 5.19 (4.11-6.48) 6.11 (4.45-8.17) 4.74 (3.34-6.54) 
Hazard ratio a Reference 0.95 (0.64-1.39) 0.99 (0.66-1.50) 
Gastrointestinal bleeding    
Number of events 61 38 29 
Incidence per 100 person-years (95% CI) 4.03 (3.08-5.17) 5.14 (3.64-7.06) 3.70 (2.48-5.31) 
Hazard ratio a Reference 0.97 (0.63-1.48) 1.04 (0.65-1.65) 
Intracranial hemorrhage    
Number of events 14 6 4 
Incidence per 100 person-years (95% CI) 0.90 (0.49-1.51) 0.79 (0.29-1.72) 0.50 (0.14-1.28) 
Hazard ratio a Reference 0.81 (0.29-2.29) 0.57 (0.18-1.85) 
Acute myocardial infarction    
Number of events 31 28 16 
Incidence per 100 person-years (95% CI) 2.01 (1.37-2.86) 3.73 (2.48-5.39) 2.02 (1.15-3.27) 
Hazard ratio a Reference 1.47 (0.85-2.54) 1.13 (0.60-2.12) 
Composite fatal cardiovascular events    
Number of events 25 7 4 
Incidence per 100 person-years (95% CI) 1.80 (1.17-2.66) 1.00 (0.40-2.06) 0.55 (0.15-1.40) 
Hazard ratio a Reference 0.42 (0.18-1.01) 0.33 (0.11-1.00) 
AF = atrial fibrillation; CI = confidence interval; HCM = hypertrophic cardiomyopathy; NOAC = Non–vitamin K antagonist oral anticoagulants. 
a Multivariate-adjusted for age, sex, heart failure, hypertension, diabetes mellitus, previous transient ischemic attack / ischemic stroke, 
previous hemorrhagic stroke, previous vascular disease, malignant neoplasm, chronic kidney disease, dyslipidemia, chronic obstructive 
pulmonary disease, obstructive hypertrophic cardiomyopathy, implantable cardioverter-defibrillator insertion, surgical myectomy and 
medications (aspirin, P2Y12 inhibitor, statin, beta blocker, angiotensin converting enzyme inhibitor / angiotensin receptor blocker, diuretics, 
dihydropyridine calcium channel blocker, non-dihydropyridine calcium channel blocker, digoxin, class Ic antiarrhythmic drugs, amiodarone, 
dronedarone, rifampin, phenytoin, azole based antifungal agents and proton pump inhibitor). 
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e-Table 5. The number of events, incidence, and risk of various events in patients with HCM and AF according to type of NOACs after 
propensity score matching. 
  
Warfarin Apixaban Dabigatran Rivaroxaban 
(n=955) (n=375) (n=458) (n=585) 
Death from all causes     
Number of events 158 16 21 43 
Incidence per 100 person-years (95% CI) 10.13 (8.61-11.83) 4.29 (2.45-6.96) 4.02 (2.49-6.14) 6.73 (4.87-9.07) 
Hazard ratio a Reference 0.39 (0.23-0.65) 0.36 (0.22-0.57) 0.53 (0.37-0.75) 
Ischemic stroke or Systemic embolism     
Number of events 115 25 40 58 
Incidence per 100 person-years (95% CI) 7.96 (6.57-9.55) 7.01 (4.54-10.35) 8.04 (5.74-10.94) 9.61 (7.30-12.43) 
Hazard ratio a Reference 0.79 (0.50-1.23) 0.86 (0.59-1.24) 1.16 (0.84-1.62) 
Major bleeding     
Number of events 78 17 25 37 
Incidence per 100 person-years (95% CI) 5.19 (4.11-6.48) 4.72 (2.75-7.56) 4.93 (3.19-7.27) 5.98 (4.21-8.24) 
Hazard ratio a Reference 0.85 (0.49-1.46) 0.88 (0.55-1.40) 1.09 (0.72-1.64) 
Gastrointestinal bleeding     
Number of events 61 15 23 28 
Incidence per 100 person-years (95% CI) 4.03 (3.08-5.17) 4.15 (2.32-6.85) 4.53 (2.87-6.79) 4.50 (2.99-6.50) 
Hazard ratio a Reference 0.93 (0.52-1.68) 1.01 (0.62-1.67) 1.04 (0.65-1.66) 
Intracranial Hemorrhage     
Number of events 14 3 1 4 
Incidence per 100 person-years (95% CI) 0.90 (0.49-1.51) 0.81 (1.67-2.36) 0.19 (0.00-1.07) 0.63 (0.17-1.61) 
Hazard ratio a Reference 0.94 (0.25-3.58) 0.25 (0.03-1.98) 0.60 (0.18-1.98) 
Acute myocardial infarction     
Number of events 31 9 10 23 
Incidence per 100 person-years (95% CI) 2.01 (1.37-2.86) 2.44 (1.12-4.63) 1.93 (0.92-3.55) 3.67 (2.33-5.51) 
Hazard ratio a Reference 1.28 (0.59-2.79) 0.80 (0.39-1.67) 1.81 (1.02-3.23) 
Composite fatal cardiovascular events     
Number of events 25 0 2 9 
Incidence per 100 person-years (95% CI) 1.80 (1.17-2.66) 0 (0-1.07) 0.42 (0.05-1.50) 1.57 (0.72-2.97) 
Hazard ratio a Reference N/A 0.21 (0.05-0.90) 0.85 (0.37-1.94) 
AF = atrial fibrillation; CI = confidence interval; HCM = hypertrophic cardiomyopathy; NOAC = Non–vitamin K antagonist oral anticoagulants. 
Edoxaban group was not shown in this table because the number of patients was small (n=86). 
a Multivariate-adjusted for age, sex, heart failure, hypertension, diabetes mellitus, previous transient ischemic attack / ischemic stroke, 
previous hemorrhagic stroke, previous vascular disease, malignant neoplasm, chronic kidney disease, dyslipidemia, chronic obstructive 
pulmonary disease, obstructive hypertrophic cardiomyopathy, implantable cardioverter-defibrillator insertion, surgical myectomy and 
medications (aspirin, P2Y12 inhibitor, statin, beta blocker, angiotensin converting enzyme inhibitor / angiotensin receptor blocker, diuretics, 
dihydropyridine calcium channel blocker, non-dihydropyridine calcium channel blocker, digoxin, class Ic antiarrhythmic drugs, amiodarone, 
dronedarone, rifampin, phenytoin, azole based antifungal agents and proton pump inhibitor). 
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e-Table 6. Baseline characteristics of overall HCM+AF in Korean NHIS and NHIS-HealS 
cohort.  
  Korean NHIS Korean NHIS-HealS cohort 
  HCM+AF 
(n=10,020) 
HCM 
(n=593) 
HCM+AF 
(n=165) 
Age 65.1 ± 12.6 60.1 ± 9.7 62.4 ± 9.5 
<65 4,354 (43.5) 345 (58.2) 93 (56.4) 
65-74 3,227 (32.2) 205 (34.6) 57 (34.5) 
≥75 2,439 (24.3) 43 (7.3) 15 (9.1) 
Men 5,492 (54.8) 380 (64.1) 103 (62.4) 
CHA2DS2-VASc score 3.53 ± 2.12 2.15 ± 1.67 2.56 ± 1.75 
Previous ischemic stroke / 
TIA 
2,596 (25.9) 69 (11.6) 20 (12.1) 
Previous hemorrhagic stroke 222 (2.2) 5 (0.8) 2 (1.2) 
Previous MI 1,567 (15.6) 52 (8.8) 23 (13.9) 
PAD 1,300 (13.0) 26 (4.4) 12 (7.3) 
Vascular disease 2,547 (25.4) 72 (12.1) 31 (18.8) 
Hypertension 8,224 (82.1) 403 (68.0) 128 (77.6) 
Diabetes mellitus 2,258 (22.5) 67 (11.3) 20 (12.1) 
Heart failure 4,540 (45.3) 108 (18.2) 52 (31.5) 
History of cancer 1,934 (19.3) 72 (12.1) 24 (14.5) 
CKD 696 (6.9) 19 (3.2) 11 (6.7) 
Dyslipidemia 7,108 (70.9) 304 (51.3) 96 (58.2) 
COPD 3,092 (30.9) 117 (19.7) 43 (26.1) 
Values are expressed as n (%) or mean ± SD. ASMD = absolute standardized mean 
diﬀerence; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; 
HCM = hypertrophic cardiomyopathy; HealS, Health Screening; MI = myocardial infarction; 
NHIS, National Health Insurance Service; NOAC = non–vitamin K antagonist oral 
anticoagulant; PAD = peripheral artery disease; TIA = transient ischemic attack; Vascular 
disease = previous MI, PAD, or aortic plaque. 
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e-Figure 1. The number of events, incidence, and risk of primary outcomes in propensity score including including ASA, P2Y12 inhibitors and 
statin matched NOAC- and warfarin-treated patients with HCM and AF. CI = confidence interval. Other abbreviations are as in e-Table 2. 
 
* Multivariate-adjusted for age, sex, heart failure, hypertension, diabetes mellitus, previous transient ischemic attack / ischemic stroke, 
previous hemorrhagic stroke, previous vascular disease, malignant neoplasm, chronic kidney disease, dyslipidemia, chronic obstructive 
pulmonary disease, obstructive hypertrophic cardiomyopathy, implantable cardioverter-defibrillator insertion, surgical myectomy and 
medications (aspirin, P2Y12 inhibitor, statin, beta blocker, angiotensin converting enzyme inhibitor / angiotensin receptor blocker, diuretics, 
dihydropyridine calcium channel blocker, non-dihydropyridine calcium channel blocker, digoxin, class Ic antiarrhythmic drugs, amiodarone, 
dronedarone, rifampin, phenytoin, azole based antifungal agents and proton pump inhibitor).  
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e-Figure 2. The number of events, incidence, and risk of fatal cardiovascular events in propensity score including ASA, P2Y12 inhibitors and 
statin matched NOAC- and warfarin-treated patients with HCM and AF. CI = confidence interval. Other abbreviations are as in e-Table 2. 
 
* Multivariate-adjusted for age, sex, heart failure, hypertension, diabetes mellitus, previous transient ischemic attack / ischemic stroke, 
previous hemorrhagic stroke, previous vascular disease, malignant neoplasm, chronic kidney disease, dyslipidemia, chronic obstructive 
pulmonary disease, obstructive hypertrophic cardiomyopathy, implantable cardioverter-defibrillator insertion, surgical myectomy and 
medications (aspirin, P2Y12 inhibitor, statin, beta blocker, angiotensin converting enzyme inhibitor / angiotensin receptor blocker, diuretics, 
dihydropyridine calcium channel blocker, non-dihydropyridine calcium channel blocker, digoxin, class Ic antiarrhythmic drugs, amiodarone, 
dronedarone, rifampin, phenytoin, azole based antifungal agents and proton pump inhibitor). 
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